The next six months will be make or break for ATH.
There definitely needs to be a catalyst event to commence an upward trajectory for the share price within that time.
Considering that the Michael J. Fox Foundation has given grants to ATH twice already, the likelihood of success is more likely than not.
To continue on the parallels between ATH and NEU, it took Neuron around 20 years to successfully commericalise any of their drugs. Observing the share price graphs over time for both ATH and NEU, ATH has had multiple upswings since 2005, whereas NEU had a U shaped chart from 2005 up until 2021.
It is wise to temper expectations and not become blindly optimistic. I do believe that there may be a positive catalyst event within the next six months. The June mid-trial results and their reaction will determine which way the share price will go long term.
ATH Price at posting:
0.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)